Clinical trial · Interventional
Anticoagulation Length in Cancer Associated Thrombosis
A Feasibility Study to Inform the Design of a Randomised Controlled Trial to Identify the Most Clinically and Cost Effective Length of Anticoagulation With Low Molecular Weight Heparin In the Treatment of Cancer Associated Thrombosis
NCT01817257CI-TRIAL-00035499ALICATterminatedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Early findings showed trial was not feasible
Summary
Brief summary (as posted)
This is a two year, multicentre, mixed methods feasibility study including a randomised controlled two-arm interventional trial, a nested qualitative study, focus groups and a United Kingdom (UK) wide survey exercise.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Deep Vein Thrombosis | — | UNRESOLVED | — |
| Pulmonary Embolus | — | UNRESOLVED | — |
| Thrombosis | — | UNRESOLVED | — |
| Venous Thromboembolism | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Low Molecular Weight Heparin (LMWH) | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- A: Continue treatment
- description
- Continue low molecular weight heparin (LMWH) at treatment dose according to body weight for further six months.
- interventionNames
- Drug: Low Molecular Weight Heparin (LMWH)
- type
- NO_INTERVENTION
- label
- B: Discontinue treatment
- description
- Discontinue low molecular weight heparin (LMWH) once patient has received six months treatment following index VTE case.
Primary outcomes (1)
- measure
- Number of eligible and recruited patients (target recruitment rate of 30% of eligible patients) over 12 months, and proportion of participants with recurrent VTEs during follow-up.
- timeFrame
- 24 months
Secondary outcomes (4)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 16 Years
Show eligibility criteria text
Inclusion Criteria: * Receiving LMWH for treatment of CAT for five months * Locally advanced or metastatic cancer * Able to self-administer LMWH, or have LMWH administered by a carer * Able to give informed consent * Age ≥16 years Exclusion Criteria: * Receiving drug other than LMWH for CAT * Contraindication to anticoagulation * Fitted with a prosthetic heart valve * Pregnant and/or lactating females
References
Publications (1)
- RESULTNoble SI, Nelson A, Fitzmaurice D, Bekkers MJ, Baillie J, Sivell S, Canham J, Smith JD, Casbard A, Cohen A, Cohen D, Evans J, Fletcher K, Johnson M, Maraveyas A, Prout H, Hood K. A feasibility study to inform the design of a randomised controlled trial to identify the most clinically effective and cost-effective length of Anticoagulation with Low-molecular-weight heparin In the treatment of Cancer-Associated Thrombosis (ALICAT). Health Technol Assess. 2015 Oct;19(83):vii-xxiii, 1-93. doi: 10.3310/hta19830. PMID 26490434